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1. Introduction 
Systemic lupus erythematosus (SLE) is a chronic autoimmune and inflammatory disease. 
There are many tissues and organs involved in the course of the disease: skin, joints, 
kidneys, serous membranes, and haematopoetic, nervous and cardiovascular systems as 
well. The course of the disease is characterized by periods of exacerbations and remissions 
(Bombardier et al., 1992).  
The crucial role in SLE pathogenesis plays dysregulation of both the innate and adaptive 
immune systems. Defective function of T cells and overactivation of B cells as well as 
defective clearance of apoptotic debris cause the production of autoantibodies, formation 
and deposition of immune complexes and, consequently, systemic tissue and organ damage 
(Shoenfeld et al., 1999; Muñoz et al., 2010).  
On the other hand, an involvement of both innate and adaptive immunity in atherosclerosis 
pathogenesis is well documented and recent data clearly characterize atherosclerosis as an 
inflammatory and autoimmune disease. The presence of monocytes/macrophages 
transformed into lipid loaded foam cells, natural killer cells, dendritic cells, mast cells and 
immunoglobulins within the plaque has been documented. Various autoantibodies have 
been reported to associate with atherosclerosis including anti-heat shock protein 60/65, anti-
oxidized low density lipoprotein (aoxLDL) and selected antiphospholipid antibodies (aPL) 
(George et al., 2000; Gordon et al., 2001; Doria et al., 2005).  
There is also a growing bulk of evidence on the strength of association between systemic 
connective tissue diseases, such SLE and premature and accelerated atherosclerosis 
development (Fischer, 2008; Doria et al., 2003) and atherosclerotic cardiovascular events are 
considered a leading cause of mortality in those patients (Borchers, 2004). Because 
traditional risk factors alone fail to fully account for accelerated atherosclerosis in SLE 
(Esdaile et al., 2001; Lee et al., 2010), it has been attributed to complex interactions between 
traditional risk factors and factors associated with the disease process and its treatment 
(Svenungsson et al., 2001; Bruce et al., 2000).  
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The purpose of this chapter was to review the risk of atherosclerotic disorders development 
in SLE as well as antiphospholipid syndrome (APS) patients, and to analyze the role of 
selected immune mechanisms in atherosclerosis pathogenesis, including potential role of 
autoantibodies, especially aPL.  
2. Atherosclerosis in systemic lupus erythematosus – The background 
Initial reports on the development of early atherosclerotic lesions in patients with SLE came 
from autopsy examinations performed by Bulkley and Roberts in 1975 (Bulkley & Roberts, 
1975). A year later, these observations were confirmed by other investigators, who developed a 
bimodal pattern of causes of mortality in this patient group, indicating that the first mortality 
peak applies to patients with active SLE, concurrent renal involvement, and recurrent 
infections, who were treated with high dose glucocorticosteroids. The second mortality peak 
was observed in patients with inactive SLE, who had been treated with glucocorticosteroids 
for many years and had previous myocardial infarction (Urowitz et al., 1976).  
Study performed at the University of Pittsburgh Medical Centre from 1980 to 1993 showed 
that women with SLE in the 35- to 44-year age group were more than 50 times more likely to 
have myocardial infarction than women of similar age in the Framingham offspring cohort. 
Overall, risk of myocardial infarction in SLE female patients was 6-fold higher in 
comparison with the general population. Of note, two thirds of all first cardiac events 
occurred in women younger than 55 years old (Manzi et al., 1997). Similar data 
demonstrated cohort study at Toronto lupus clinic. The rate of myocardial infarction in 
lupus patients was 5 per 1000 persons in comparison with 1 per 1000 persons in the general 
population from 1993 to 1994 and the mean age of first cardiac episode was 49 years in SLE 
patients compared with the peak incidence in the general population aged 65 to 74 years 
(Bruce et al., 2000).  
Furthermore, the report from the Toronto SLE cohort study showed among 10.9% of 1087 
patients at least one atherosclerotic vascular event either cardiac, cerebrovascular or 
peripheral vascular. The prevalence of coronary events was as follows: myocardial 
infarction – 2.2%, angina – 7.2% and sudden death – 0.3% (Urowitz et al., 2007). Comparable 
results provided large lupus cohorts studies in Pittsburgh and Baltimore showing the 
occurrence of clinical symptoms of coronary artery disease in 6.6% and 8.3% patients 
respectively (Manzi et al, 1997; Petri et al, 1992). 
Study performed in 129 SLE patients at Department of Rheumatology and Internal Diseases 
Pomeranian Medical University, which focused on prevalence and selected risk factors of 
ischemic heart disease and myocardial infarction, demonstrated ischemic heart disease in 20 
(15.5%) SLE patients and myocardial infarctions in 9 (6.97%). Ischemic heart disease and 
myocardial infarction were related to high activity of SLE, odds ratio (OR): 7.18; p = 0.012 
and OR: 27.3; p = 0.006 respectively. Ischemic heart disease was significantly more common 
in older patients (52.8 years versus 42.2 years; p = 0.0008), in patients with hypertension (p < 
0.05) and with impaired glucose tolerance (OR: 8.44; p = 0.03). Myocardial infarction was 
significantly associated with high uric acid level (OR: 5.01; p = 0.052) and impaired glucose 
tolerance (OR: 7.42; p = 0.047) (Ostanek et al., 2006a).  
Our next study was aimed at the assessment of cardiovascular abnormalities in SLE patients 
in echocardiographic examination. The following pathologies were significantly more 
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frequent in SLE patients: pericardial involvement (58%), organic changes of the mitral valve 
cusps (54%), organic changes of the aortic valve cusps (36%), widening of the aortal lumen 
(35%), enlargement of the atrium (18%), hypokinenesis of the left ventricle myocardial 
muscle (15%). Moreover, pericarditis was marker of high activity of the disease (OR: 3.89; 
95% confidence interval (CI): 1.05-14.40; p = 0.042) and enlargement of the left atrium  
was significantly associated with the low level of HDL-cholesterol (OR: 6.94; 95%CI: 1.17-
40.9; p = 0.033) (Ostanek et al., 2006b). 
These data clearly show that cardiac involvement is a frequent and early systemic 
complication in the course of SLE. Cardiovascular disorders are often associated with high 
activity of the disease and classic risk factors are poorly related to these manifestations.  
Additionally, many reports on subclinical atherosclerosis development in SLE patients have 
been published in recent years. Early diagnosis of subclinical changes can be established 
using noninvasive imaging techniques, which enable to assess atherosclerotic lesions on 
different stages of their development. The subclinical atherosclerosis was reported in 30% to 
67% of SLE patients (Manzi et al., 1999; Fischer, 2008). 
Endothelial dysfunction is a widespread phenomenon which represents an early stage of 
atherogenesis and it is established as a precursor and denominator of atherosclerotic events 
(Celermajer et al., 1992). Techniques designed to assess endothelial function are based on 
measurement of brachial artery reactivity in response to changes in blood-flow caused by 
passive congestion (flow-mediated vasodilatation, which is dependent on endothelial 
function) (Corretti et al., 2002). Studies performed in SLE patients documented an impaired 
endothelial function and this fact was attributed to reduced nitric oxide bioavailability 
resulting from increased oxidative stress in the course of SLE (El-Magadmi et al., 2004; Kiss 
et al., 2006; Wright et al., 2006). Furthermore, impairment of endothelial function remained 
significant even after adjustment for other classic atherosclerosis risk factors and the authors 
suggested that SLE is an independent risk factor for endothelial dysfunction (El-Magadmi et 
al., 2004). Interestingly, study completed in young females with SLE (mean age 29.4 years) 
disclosed vasomotor dysfunction of the coronary arteries, thus indicating the presence of 
subclinical coronary artery disease in these patients (Hirata et al., 2007). 
Early stage of atherosclerosis can be also defined as a reduction of vascular elasticity. 
Measurement of pulse wave velocity is the most commonly used approach to assess 
stiffness of the large arteries (Tanaka et al.; 1998). Evaluation of aortal wall elasticity in 
patients with SLE was the subject of numerous clinical studies. They all documented 
increased aorta stiffness in SLE patients and its relationship to a higher risk of 
cardiovascular events (Selzer et al., 2001; Bjarnegård et al., 2006) and its association with 
active inflammation in analyzed patient groups (Roman et al., 2005). 
Ankle-brachial index measurement enables to identify atherosclerotic lesions in the arteries 
of the lower extremities. Because of its simplicity and low cost it is recommended for use in 
routine diagnostic evaluation especially to detect asymptomatic atherosclerotic lesions. 
Furthermore, this test is used in the stratification of overall cardiovascular risk (Graham et 
al., 2007). Clinical studies confirmed the usefulness of ankle-brachial index in detecting early 
atherosclerotic changes in SLE patients (Theodoridou et al., 2003). 
Measurement of carotid intima-media thickness (CIMT) with B-mode ultrasound is a 
surrogate marker of atherosclerosis. The utility of CIMT in the evaluation of subclinical 
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atherosclerosis in SLE patients has been well documented (Svenungsson et al., 2001; Doria et 
al., 2003; Fischer, 2008). This method is often used in epidemiological studies (Denarié et al., 
2000; Sun et al., 2002) and also in assessing total cardiovascular risk (Ebrahim et al., 1999). 
Emphasis is put on a correlation between CIMT and the development of coronary artery 
disease (O’Leary et al., 1999; Takashi et al., 2002) and cerebrovascular manifestations 
(Chambless et al., 2000; Touboul et al., 2005). These findings were supported by our study, 
which also disclosed association between high cumulative dose of glucocorticosteroids and 
CIMT as well as carotid plaques development and confirmed less significance of classic risk 
factors for atherosclerosis in SLE patients (Fischer, 2008). 
We also showed the clinical usefulness of vascular resistance assessment in SLE patients. Our 
study conducted in 92 patients was based on high resistance index measurement, which was 
calculated from Doppler spectrum of the popliteal arteries. Significantly lower values of high 
resistance index were observed in SLE patients, especially those with coexistence of APS, 
compared with the controls. This indicates that high resistance index measurement can be 
used to evaluate early, subclinical lesions in vessels in the course of SLE (Walecka et al., 2004). 
The detailed analysis of noninvasive imaging techniques and their usefulness in early, 
subclinical atherosclerotic changes detection in SLE patients is reviewed elsewhere (Fischer 
& Brzosko, 2009). However, from this short description it can be concluded that lupus 
patients are at high risk of atherosclerosis as well as cardiovascular disorders development. 
Atherosclerotic lesions at an initial stage can be detected by means of increasingly 
sophisticated diagnostic tools, which allow evaluating systemic atherosclerosis, and they 
should represent an essential component of the diagnostic evaluation of SLE that is 
necessary to implement appropriate preventive and therapeutic procedures.  
Furthermore, studies performed in children and adolescents with SLE strongly evidenced 
the premature atherosclerosis development in the course of the disease. On the other hand, 
they also suggest necessity of vascular testing with different imaging methods (Schanberg et 
al., 2009; Boros et al., 2011). Moreover, the authors emphasized a significant impact of 
applied treatment on atherosclerotic lesions development (Schanberg et al., 2009) and lipids’ 
metabolism (Boros et al., 2011) in pediatric SLE. Traditional risk factors predictive of 
increased atherosclerotic risk, similarly like in adult SLE patients, had limited clinical 
significance (Schanberg et al., 2009).  
Understanding risk factors in the development of atherosclerosis in the course of SLE, 
especially those associated with the disease process, and early identification of patients at 
risk will enable to avoid irreversible cardiovascular damage, which represents the primary 
cause of morbidity and mortality in SLE patients.  
3. Association between atherosclerosis and antiphospholipid antibodies in 
systemic lupus erythematosus – Related mechanisms 
3.1 Antiphospholipid antibodies and lupus-related atherosclerosis – Clinical studies 
Accelerated atheromatosis is a well recognized clinical problem in SLE patients. Systemic 
lupus erythematosus has been considered an independent risk factor for endothelial 
dysfunction, an early stage in atherogenesis (El-Magadmi et al., 2004), and an increased 
CIMT (Colombo et al., 2007). Because the cardiovascular risk factors in SLE significantly 
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differ from those in the general population, many clinical as well as experimental studies 
investigated the role of SLE-related immune and inflammatory mechanisms of 
cardiovascular involvement. 
The analysis of preclinical vascular disease in SLE and primary antiphospholipid 
syndrome (PAPS) patients showed higher prevalence of carotid plaque in SLE patients 
with coexistent APS than in patients with PAPS. However, the relationship with aPL 
(anticardiolipin antibodies – aCL and lupus anticoagulant – LA) was not found (Jiménez 
et al., 2005). On the other hand, the study performed in 200 SLE patients focused on 
evaluation of classic and lupus-related factors associated with CIMT and carotid plaque 
showed that aPL (aCL and/or LA) are independent risk factors for subclinical 
atherosclerosis (Ahmad et al., 2007). The multiethnic cohort study LUMINA which 
determined the baseline risk factors associated with the subsequent occurrence of vascular 
events (cardiovascular, cerebrovascular and peripheral vascular) confirmed aPL as 
independent predictors of these complications (OR = 4.7; 95%CI: 1.8-13.2) (Toloza et al., 
2004). Similarly, study of longitudinal cohort of SLE patients also found aPL, and 
especially anti-beta2-glycoprotein I antibodies (aβ2-GPI) and aCL, baseline predictors of 
the first ever cardiovascular event (Gustafsson et al., 2009). Interestingly, an investigation 
performed in rheumatoid arthritis patients (premenopausal women, non-diabetic, non-
hypertensive) disclosed advanced atherosclerosis in these patients shown as an increase of 
CIMT and plaque formation. Antiphospholipid antibodies (aCL and aβ2-GPI) were 
significantly more frequent in patients group supporting an idea that these antibodies 
represent an important risk factor for atherosclerosis in patients with rheumatoid arthritis 
(Pahor et al., 2006). 
In accordance, our study on subclinical atherosclerosis in SLE patients which analyzed 
many serologic markers of the disease including aPL (aCL, LA, aβ2-GPI, anti-prothrombin 
antibodies (aPT) and aoxLDL) disclosed interesting association between CIMT and 
selected aPL. The presence of both isotypes of aCL IgG or IgM, LA and aPT IgA 
significantly increased the risk of thickening of intima-media and the relative risk was 4.4 
(95%CI: 1.3-14.9), 4.0 (95%CI: 1.1-19.4) and 5.5 (95%CI: 1.1-30.2), respectively. We also 
confirmed the relationship between coexistence of APS and early atherosclerotic 
abnormalities in analyzed patients group. Additionally, the presence of aCL IgM 
significantly influenced carotid atherosclerotic plaque development (OR = 3.8; 95%CI: 1.1-
13.1) (Fischer et al., 2007). Furthermore, our evaluation of risk factors for ischemic heart 
disease and myocardial infarction in SLE patients showed that these manifestations were 
more frequent in patients with coexistent APS (OR = 4.2 and 12.8, respectively). Ischemic 
heart disease was associated with aCL IgG (OR = 2.9) and myocardial infarction with aCL 
IgG and/or IgM (OR = 5.6) (Ostanek et al., 2006a). Furthermore, our next study on 
echocardiographic assessment of cardiovascular abnormalities documented a significant 
association between mitral valve involvement and aβ2-GPI IgA (OR = 13.63; 95%CI: 1.2-
139.8) as well as aPT IgA (OR = 17.5; 95%CI: 1.3-231.0). Anticardiolipin antibodies IgG 
were significantly related to the increased amount of pericardial fluid (OR = 2.5; 95%CI: 
1.1-6.1) (Ostanek et al., 2006b). 
An investigation undertaken to examine the relationship of aPL with valvular, myocardial 
and arterial disease in SLE also documented significant correlation with mitral valve 
nodules and mitral regurgitation. Though, aPL were not related to myocardial hypertrophy, 
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systolic dysfunction, coronary or carotid atherosclerosis and other analyzed vascular 
abnormalities (Farzaneh-Far et al., 2006).  
Current studies also did not prove any association between aPL and atherosclerosis in SLE 
patients. Results from the Hopkins’ Lupus Cohort regarding the relation of aPL (aCL, LA 
and aβ2-GPI) to thrombosis and non-thrombotic manifestations as well as atherosclerotic 
changes disclosed their significant relationship with venous and arterial thrombosis and 
selected cerebrovascular complications. Lupus anticoagulant was a sole antibody associated 
with myocardial infarction but there was no connection between aPL and CIMT, plaques 
and coronary calcification (Petri, 2010). In addition, the investigation focused on risk factors 
for coronary artery disease performed in SLE patients of the LASER study did not confirm 
any relation of aPL to cardiovascular risk (Haque et al., 2010). 
3.2 Selected pathomechanisms in atherogenesis – The role of antiphospholipid 
antibodies 
In regard to contrary reports from clinical studies there is large evidence that aPL may 
display proatherogenic effects which was disclosed by in vitro and in vivo studies. 
Paraoxonase, an enzyme present in the arterial wall and in the HDL particle, inhibits LDL 
oxidation and is the major contributor to the antioxidant defense of plasma (Ames et al., 
2009b). The paraoxonase gene is located at q21-q22 on the long arm of chromosome 7 
(Durrington et al., 2001). It was shown in animal model that mice in which the paraoxonase 
gene was removed are devoid of protection against lipid peroxidation and HDL isolated 
from these mice were unable to prevent LDL oxidation in a co-cultured cell model of the 
artery wall (Jara et al., 2003). Furthermore, another experiment on non-lupus murine model 
investigated whether aCL could affect oxidant/antioxidant balance as an early biochemical 
step of APS. This study documented that aCL are associated with the decreased 
paraoxonase activity and reduced nitric oxide (sum of nitrite and nitrate) levels (Delgado 
Alves et al., 2005). 
The study performed in SLE and PAPS patients paid attention to prevalence of anti-high-
density lipoprotein antibodies (aHDL) and their relationship with aCL, aβ2-GPI and 
paraoxonase activity. Patients with SLE had decreased levels of HDL and its subfraction 
HDL2 and HDL3 and this lipoprotein or some of its components may represent target 
antigens for aHDL, which were significantly elevated in both analyzed patients groups. 
Moreover, there was strong inverse correlation between aHDL IgG and paraoxonase activity 
in SLE patients. In PAPS group, paraoxonase activity was inversely correlated with aCL 
IgG, aβ2-GPI IgG and IgM. However, on the basis on multiple regression model only aβ2-
GPI IgG were found an independent predictor of decreased paraoxonase activity (r= -0.483, 
p = 0.003). The reported interactions may be relevant to the development of atherosclerosis 
in SLE and PAPS (Delgado Alves et al., 2002). Other observations also supported findings 
on the role of paraoxonase activity in SLE-related vascular abnormalities. The significantly 
decreased paraoxonase activity was found in SLE patients as compared to controls. Notably 
reduced paraoxonase activity was shown especially in lupus patients suffering from 
cardiovascular and cerebrovascular events (angina pectoris, myocardial infarction, transient 
ischemic attack, ischemic stroke) as compared to patients without such manifestations. 
Interestingly, also disturbed microcirculation was significantly associated with reduced 
www.intechopen.com
Antiphospholipid Antibodies and Their Association with Atherosclerotic Changes  
in Patients with Systemic Lupus Erythematosus – Review of Literature and Own Experiences 
 
103 
paraoxonase activity in patients with Raynaud’s phenomenon. These observations suggest 
that decreased paraoxonase activity in SLE patients may have pathogenic significance in 
accelerated atherosclerosis and its complications development (Kiss et al., 2007). More recent 
study evaluated vascular structure and function in women with aPL and assessed their 
relationship with paraoxonase activity. Patients with aPL in comparison with the controls 
had greater CIMT and arterial stiffness measured by pulse wave velocity, and lower flow-
mediated dilatation pointing out an impaired endothelial function. Paraoxonase activity was 
lower in women with aPL than in controls and was inversely associated with CIMT and 
pulse wave velocity in these patients. Additionally, it was proved that HDL from women 
with aPL reduced nitric oxide bioavailability. That group was found to have an impaired 
anti-inflammatory and antioxidant properties (Charakida et al., 2009). 
Some experimental studies clearly pointed out that aPL may enhance the development of 
atherosclerosis by oxidative modification of lipoproteins [LDL or Lp(a)] and by promoting 
the uptake of subendothelial lipoproteins by macrophage scavenger receptors causing an 
excessive intracellular accumulation of oxLDL and foam cell formation (Bassi et al., 2007). 
Oxidized LDL has chemotactic, proinflammatory and toxic properties, and promotes T-cell 
activation (Frostegård, 2005). The presence of oxLDL in atherosclerotic lesions in animal 
models and in humans has been shown (George et al., 2000). Enhanced oxidative stress and 
lipid peroxidation were also demonstrated in SLE patients (Frostegård, 2005). 
A number of studies were addressing to the role of aoxLDL in atherosclerosis development 
in SLE patients. In our study we did not find any association between subclinical 
atherosclerotic lesions and these antibodies (Fischer et al., 2007). Other reports also provided 
discrepant results. The study of SLE patients in which aoxLDL and antibodies against 
oxidation epitopes in LDL were assessed showed aoxLDL more frequent in SLE patients 
with a history of cardiovascular disease in comparison to the controls (Svenungsson et al., 
2001). It was also demonstrated that the titres of these IgG antibodies are high in SLE 
patients and that there is a good correlation between aoxLDL levels and the maximum 
intima-media thickness (Doria et al., 2003). High titres of aoxLDL IgG were also found in 
hypertensive SLE patients (Radulescu et al., 2004). On the other hand, the analysis of 
aoxLDL in SLE patients with and without APS, although, documented high frequency of 
aoxLDL in SLE patients with coexistent APS (not with PAPS) but did not find evidence 
suggesting that these antibodies may be associated with atherosclerosis. However, weak 
significant correlation between aoxLDL IgG and aCL IgG as well as aβ2-GPI IgG and 
association with a history of venous thrombosis were confirmed (Hayem et al., 2001).  
Noteworthy, a number of early studies performed in the general population showed that 
aoxLDL are associated with myocardial infarction (Erkkilä et al., 2000) and, moreover, the 
effect was independent of LDL-cholesterol levels (Puurunen et al., 1994). Similarly, in 
patients with early-onset peripheral vascular disease the titres of aoxLDL were increased. 
There was also an interesting tendency for higher antibody levels in patients with more 
extensive atherosclerotic lesions (Bergmark et al., 1995). On the contrary, there are even 
reports on an inverse correlation between aoxLDL titre and CIMT (Fukumoto et al., 2000). 
More detailed analysis indicated that in humans aoxLDL are low at an early stage of 
cardiovascular disease development in nonautoimmune disease and in healthy individuals 
but they are increased at later stages and in more advanced disease (Frostegård, 2005).  
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Furthermore, these antibodies are heterogeneous in immunoglobulin class and in their 
epitope specificity and affinity. Thus, present opinion indicates that IgG aoxLDL antibodies 
seem to be pathogenic for subclinical atherosclerosis development in SLE patient (Bassi et 
al., 2007). While, IgM aoxLDL are thought to provide protection against proinflammatory 
oxidized moieties, which was shown in animal models (Matsuura et al., 2006a). 
Crossreactivity between selected aPL and aoxLDL is an additional issue. Cardiolipin was 
found a component of LDL and the crossreactivity of aCL and aoxLDL has been 
documented (McMahon & Hahn, 2007). In addition, in vitro macrophage uptake of oxLDL 
has been significantly enhanced in the presence of beta2-glycoprotein I (β2-GPI) and aβ2-
GPI IgG (Hasunuuma et al., 1997). The macrophage uptake of liposomes containing β2-GPI 
ligands also has been demonstrated indicating the possible proatherogenic role of aβ2-GPI 
IgG (Matsuura et al., 2005). The in vitro interaction between oxLDL and β2-GPI occurs 
quickly and evolve into stable covalent bonds making the complexes nondissociable. The 
similar mechanism has been postulated in vivo in the intima of arterial wall. Circulating 
oxLDL/β2-GPI complexes were demonstrated in SLE patients. In vitro investigations 
showed enhanced macrophage uptake of IgG immune complexes with oxLDL/β2-GPI. 
Measurement of oxLDL/β2-GPI complexes may represent a more physiological, clinically 
relevant, and accurate way of assessing oxidative stress and atherogenesis (Lopez et al., 
2007).  
The prolonged persistence of oxLDL/β2-GPI complexes can stimulate immune mechanisms 
and antibody production (aoxLDL/β2-GPI) that contribute to atherosclerosis (Lopez et al., 
2007). The study performed in patients with selected systemic connective tissue diseases 
including SLE and APS showed aoxLDL/β2-GPI IgG significantly increased in SLE patients. 
Significantly higher levels of these antibodies were also confirmed in SLE patients with 
coexistence of APS with a positive predictive value for APS of 90%. Moreover, the predictive 
value for arterial thrombosis was 94%. It was considered that the presence of circulating 
oxLDL/β2-GPI complexes and IgG antibodies to these complexes indicates significant 
vascular injury and oxidative stress and proved an active role of autoimmune-mediated 
atherothrombosis (Matsuura et al., 2006b). Further studies disclosed contribution of these 
complexes and related antibodies to organ damage (especially renal involvement) and 
confirmed their association with thrombotic events in SLE patients (Bassi et al., 2009). Their 
relationship with both CIMT and reduced paraoxonase activity in PAPS patients has been 
also demonstrated (Ames et al., 2006). 
Antiphospholipid antibodies may also have a direct effect on endothelium. Early in vitro 
studies documented that IgG from patients with high titre of aCL enhanced monocyte 
adhesion to human umbilical vein endothelial cells via mechanism dependent on β2-GPI 
(Simantov et al., 1995). Additionally, aβ2-GPI mediates binding of aCL to endothelial cells 
leading to their activation, and contributing to thrombosis and thrombocytopenia in patients 
in whom aCL were present (Le Tonquéze et al., 1995).  
The other atherothrombotic mechanism has been also postulated based on decreased 
binding of annexin V to endothelial cells in the course of SLE. Among analyzed antibodies 
aCL IgG significantly influenced this decreased binding. Moreover, there was a positive 
association between annexin V binding and CIMT (r = 0.73, p < 0.001). Interestingly, 
immunochistochemical analysis revealed presence of annexin V in all human atherosclerotic 
plaques tested, especially at sites prone to rupture (Cederholm et al., 2005). The novel in 
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vitro findings confirmed these observations showing reduced annexin A5 binding to 
endothelium by monoclonal aCL IgG via dose-dependent mechanism. Of note, 
preincubation of intravenous (IV) immunoglobulins at therapeutically relevant doses with 
aPL and monoclonal aCL restored annexin A5 binding to comparable levels when normal 
healthy serum was used. On the contrary, IV immunoglobulins per se reduced annexin A5 
binding to endothelial cells when added to normal healthy serum suggesting that some 
antibodies in IV immunoglobulins may be involved in atherothrombosis and cardiovascular 
disease development during IV immunoglobulins treatment (Frostegård et al., 2010). The 
study conducted to investigate the association of plasma annexin V, anti-annexin V 
antibodies and aCL with acute myocardial infarction showed that patients suffering from 
acute myocardial infarction had significant low levels of annexin V and high levels of 
antibodies to this protein (p = 0.002 and p = 0.004, respectively). This combination indicated 
a hypercoagulable state in patients with acute myocardial infarction which was not related 
to traditional cardiovascular risk factors because plasma antibodies and annexin V levels 
were not correlated with hypertention, diabetes mellitus, hyperlipidemia, gender, age and 
smoking habits (Shojaie et al., 2009). 
Antiphospholipid antibodies may act at various stages of atherogenesis process: activating 
endothelium, mediate adhesion of leukocytes and potentiating the uptake of oxLDL by 
scavenger receptor to generate foam cells. Crossreactivity of aPL to lipoprotein antigens 
may further facilitate atherogenesis (Narshi et al., 2011). However, SLE characteristics can 
mask the pathogenic role of some of autoantibodies in the development of atherosclerosis 
(Bassi et al., 2007). Therefore, the utility of aPL in related to SLE cardiovascular risk 
estimation in clinical practice remains controversial. 
4. Atherosclerosis in primary antiphospholipid syndrome 
Primary antiphospholipid syndrome is a systemic autoimmune disease characterized by the 
occurrence of arterial or venous thrombosis or pregnancy complications together with the 
persistence of aPL in the absence of other known autoimmune conditions (Miyakis et al., 
2006). 
Although, an accelerated atherosclerosis in APS coexistent with SLE is a well known clinical 
problem (Fischer, 2008; Belizna et al.; 2007; Roman et al., 2001). In patients with PAPS 
arterial ischemic events may occur even in the absence of evident atherosclerosis. Therefore, 
there is the risk of misdiagnosing young patients with potentially life-threatening symptoms 
including myocardial infarction (Gualtierotti et al., 2011). Furthermore, recent reports 
showed that a number of PAPS patients can develop Syndrome X defined as a condition 
with the presence of angina-like chest pain, positive response to stress testing and normal 
coronary angiograms often existing in the absence of traditional cardiovascular risk factors. 
It is suggested that microvascular abnormalities secondary to endothelial dysfunction may 
cause this complication development (Sangle et al., 2008).  
Accordingly, there is accumulating evidence to confirm an impaired endothelial function in 
the course of PAPS. The study performed in 31 young patients with PAPS (mean age 35 
years) documented a significant endothelial dysfunction in comparison with the controls. 
Moreover, patients with arterial involvement had importantly more prominent decrease of 
flow-mediated dilatation in comparison with patients with venous involvement. The 
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presence of classic atherosclerotic risk factors did not differ between patients and the control 
group. Additionally, association between aCL IgG/IgM as well as variety of therapy and 
impaired endothelial function was not confirmed (Mercanoglu et al., 2004). Similarly, 
another study in which parameters of endothelial dysfunction were analyzed also proved 
endothelial dysfunction in 25 PAPS patients and, in addition, showed significant inverse 
correlation between endothelial dysfunction and selected markers of endothelial 
activation/damage (Štalc et al., 2006). In contrast, another group did not show in 20 PAPS 
patients neither impaired endothelial function, pathological values of plasma markers of 
endothelial or platelet activation nor progenitor and mature endothelial cells, suggesting 
that the alteration leading to thrombosis in PAPS concerns primarily the clotting system 
(Gresele et al., 2009). On the other hand, results showed in 44 PAPS patients in whom 
subclinical atherosclerosis was evaluated by endothelial function assessment and CIMT 
measurement clearly documented both abnormal values of CIMT and parameters of 
endothelial function. Moreover, there was negative linear correlation between flow-
mediated vasodilation and CIMT. The von Willebrand factor level was also significantly 
higher in PAPS patients than in the control group, reflecting an endothelial injury. Similarly 
to other reports, significant difference regarding traditional cardiovascular risk factors 
between PAPS patients and the controls was not shown. Moreover, there was no correlation 
between impaired endothelial function and aPL serum levels. The authors pointed out that a 
relationship exists between the presence rather than the amount of aPL and subclinical 
atherosclerosis (Der et al., 2007). However, study performed in subjects with idiopathic aPL 
showed association between aCL IgG titre and CIMT. In addition, it confirmed aCL IgG as 
well as homocysteine and fibrinogen as independent predictors of CIMT indicating that 
measurement of homocysteine and fibrinogen may help to identify aPL patients who are 
more likely to develop atherosclerosis (Ames et al., 2002). More recent studies also 
confirmed a usefulness of CIMT measurement in a detection of early atherosclerotic changes 
and showed an association between CIMT and aPL in thrombotic PAPS patients (Ames et 
al., 2009a) as well as in patients with APS secondary to SLE (Belizna et al., 2008). 
Furthermore, a relationship between increased CIMT and stroke in the course of PAPS was 
reported (Medina et al., 2003).  
A number of studies confirmed a clinical utility of other noninvasive imaging methods in 
atherosclerosis diagnosis in PAPS patients showing increased arterial stiffness (Belizna et al., 
2008; Charakida et al., 2009) or abnormal ankle-brachial index (Barón et al., 2005). 
Epidemilogical data from a multicenter, consecutive, prospective study on 1,000 APS 
patients disclosed at disease onset that some of the most common manifestations were 
cerebrovascular disorders (stroke – 13.1% and transient ischemic attack – 7.0%). Myocardial 
infarction was present in 2.8% of patients. Though, cumulative clinical features during the 
evolution of disease showed a higher prevalence of both neurologic manifestations 
(including stroke – 19.8% and transient ischemic attack – 11.1%) as well as selected cardiac 
complications – myocardial infarction (5.5%), angina (2.7%) and coronary bypass 
rethrombosis (1.1%) (Cervera et al., 2002). Myocardial infarction and stroke were also the 
most common causes of death in this cohort (18.9% and 13.2% respectively) (Cervera et al., 
2009).  
Accelerated atherosclerosis in the course of PAPS should be considered an example of 
atherothrombotic event caused by aPL playing both proatherogenic and prothrombotic role 
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(Der et al., 2007). Selected cardiovascular complications can exist without overt 
atherosclerosis (Gualtierotti et al., 2011). Therefore, early diagnosis of subclinical 
atherosclerotic changes with different imaging methods is extremely important. 
5. Relationship between antiphospholipid antibodies and atherosclerosis in 
the general population 
The new theories developed in the last century enabled the better understanding of 
atherosclerosis pathogenesis. The “response-to-injury” theory formulated by Ross and 
Glomset in 1973 showed endothelial damage to be a key initiator of atherosclerotic lesions. 
Further investigations disclosed that endothelial cells have the potential to play an active 
role both in the formation of lipid-laden foam cells and in the accumulation of necrotic 
tissue which are hallmarks of the atherosclerotic lesion (DiCorleto & Chisolm, 1986). The 
role of immunological and inflammatory factors in the pathogenesis of atherosclerotic 
lesions was confirmed in the 1990s (Ross, 1993). The interplay of inflammatory and 
immunological mediators including cytokines, chemokines, adhesion molecules, leukocytes, 
complement as well as antibodies, promotes damage of endothelium and progressive 
atherosclerotic plaque development (Hansson, 2001). 
The potential role of aPL in atherosclerosis and atherosclerotic vascular events development 
in the general population has been extensively studied over the last few decades.  
A case-control study, which included patients operated on for atherosclerotic peripheral 
vascular disease before 50 years of age, tested the hypothesis whether antibodies 
associated with an immune/inflammatory damage to the vascular wall were associated 
also with early atherosclerosis. Subjects were compared for the prevalence of aCL and 
anti-endothelial cell antibodies (AECA), classic risk actors for atherosclerosis and signs of 
inflammation. The presence of analyzed antibodies significantly differed between patients 
and controls (p < 0.05). The presence of aCL and AECA was confirmed in 14.5% and 
12.9% patients, respectively. None of the patients with antibodies had clinical or 
laboratory features of systemic connective tissue disease. The patients had higher values 
of laboratory parameters suggesting inflammation. However, there was no correlation 
between the presence of antibodies and laboratory signs of inflammation. Interestingly, 
the occurrence of hyperlipidemia/dyslipidemia was lower in patients with aCL and/or 
AECA, as compared to patients without these antibodies suggesting that these antibodies 
have a role in vascular damage (Nityanand et al., 1995). These observations were 
confirmed by other investigators. The next study analyzed patients who had undergone 
elective supraiguinal (aortofemoral, femoral-femoral, iliac endarterectomy, or 
axillofemoral bypass grafting) or infrainguinal procedures for atherosclerotic occlusive 
disease. Patients were assessed for the presence of aPL- aCL IgG, IgM, IgA and LA and 
their association with the progression of the disease. There was statistically significant 
difference between aPL positive and negative patients in the progression of arterial 
occlusive disease in at least one artery during the 9 years follow-up (73% versus 37%, p < 
0.0001). Furthermore, multivariate logistic regression analysis was used to test the effect 
of atherosclerotic risk factors on disease progression. Antiphospholipid antibodies status 
and traditional atherosclerotic risk factors, heart disease, chronic renal insufficiency, 
warfarin therapy and type of procedure were examined. Of note, only the presence or  
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absence of aPL significantly contributed to progression in those patients who had 
undergone elective lower extremity revascularization for chronic ischemia (Lam et al., 
2001). Interesting study was performed in 411 patients with atherosclerotic vascular 
disease who underwent at least one of the following events: unstable angina, myocardial 
infarction, angioplasty, coronary artery bypass surgery, claudication, transient ischemic 
attack and ischemic stroke. All subjects were tested for the presence of aCL IgG and IgM. 
It was shown on the basis of stepwise logistic regression analysis that for any 
atherosclerotic vascular disease event, significant independent, positive correlates 
included selected classic atherosclerotic factors (age, diabetes, male gender, hypertension 
and the family history of vascular atherosclerotic disease) and aCL IgM. Moreover, for 
those patients having a myocardial infarction, coronary bypass surgery and/or 
angioplasty, aCL IgM was a significant independent positive predictor of cardiovascular 
events. Additionally, aCL IgM was a positive significant independent risk factor for 
vascular events, including myocardial infarction, at ≤ 55 years of age. Levels of aCL IgG 
were positively associated with aCL IgM. The authors suggested that aCL IgG and IgM 
should be routinely measured as ancillary atherothrombotic risk factors in all patients 
with atherosclerotic vascular disease events, in patients at high risk of atherosclerotic 
vascular disease, and in patients where thrombosis is a major pathoetiology (Glueck et al., 
1999). These results are consistent with the data from a prospective cohort study of the 
relation of aCL and risk of myocardial infarction and cardiac death performed in middle-
aged men of Helsinki Heart Study. The levels of aCL IgG were significantly higher in 
subjects than controls (p < 0.005). Persons with the highest levels of aCL IgG were at 2-
fold higher risk of myocardial infarction and the risk was independent of traditional risk 
factors for atherosclerosis (Vaarala et al., 1995). The clinical importance of high levels of 
aCL also documented study of patients with focal cerebral ischemia harboring aCL of at 
least 10 GPL units at the time of their index event. Patients were prospectively followed to 
estimate the effect of aCL titer on time to and risk of subsequent thrombo-occlusive events 
(stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, 
myocardial infarction) and death. Patents with aCL titers > 40 GPL were younger, had 
more prior strokes, more frequent subsequent thrombo-occlusive events and death, and a 
shorter median time to event (Levine et al., 1997). The more recent study performed in 432 
Taiwanese adults with cerebral ischemia disclosed an interesting impact of aCL IgG. 
Patients were classified into five subtypes according to the cause of cerebrovascular event: 
large-artery atherosclerotic disease, stroke of unknown etiology, small-artery occlusive 
disease, cardioembolism, and stroke of other known etiology. It was shown that aCL IgG 
selectively increases in patients with large-artery atherosclerosis and stroke of unknown 
etiology, reflecting selective activation of humoral immunity for aCL in the pathogenesis 
of cerebral ischemia (Chen et al., 2006). On the other hand, a multicenter cohort study 
performed in premenopausal women with a first myocardial infarction or ischemic stroke 
showed a significant relationship of LA to myocardial infarction (OR = 5.3) and ischemic 
stroke (OR = 43.1). Anti-beta2-glycoprotein I antibodies also were associated with an 
increased risk of ischemic stroke (OR = 2.3). However, neither aCL nor aPT affected the 
risk of those manifestations (Urbanus et al., 2009). 
Finally, an inclusion of aPL to the estimation of risk of atherothrombotic vascular events 
development in the general population seems to be justified, especially in young patients 
without coexistent classic cardiovascular risk factors. 
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6. Selected non-criteria antiphospholipid antibodies and their relationship to 
atherosclerosis 
Early studies performed in 1990s have already put attention to aPL directed against non-
cardiolipin antigens in SLE. They documented significantly increased levels of selected aPL 
in lupus patients and described wide profile of potential antigens (Maneta-Peyret et al., 
1991; Toschi et al. 1993).  
Many studies on the clinical significance of aPT have been reported in APS patients (Galli 
& Barbui, 1999) and several pathogenic mechanisms providing to hypercoagulable state of 
APS via aPT were suggested (Atsumi & Koike, 2002). Interesting study performed in 
animal model provided the first direct evidence for thrombus induction by aPT. Mice were 
immunized with prothrombin, β2-GPI or β2-GPI followed by prothrombin. The presence of 
clinical manifestations of APS was analyzed. Thrombosis was studied in an ex-vivo model 
in which aorta was sutured for 1 minute and the presence or absence of visible thrombus 
was qualitatively evaluated. All prothrombin-immunized mice developed thrombus within 
the aorta confirming prothrombotic properties of aPT (Haj-Yahja et al., 2003). Moreover, 
the study performed in middle-aged men with dyslipidemia showed higher levels of aPT 
in patients who developed myocardial infarction or cardiac death than in controls. The 
relative risk of these complications was 2.5-fold higher (95%CI: 1.2-5.3) in patients with aPT 
(Vaarala et al., 1996). These data were supported by the investigation performed in young 
women with acute ischemic stroke. Anti-prothrombin antibodies were more frequent in 
patients with cerebrovascular manifestations in comparison with the healthy controls (OR 
= 182.0; 95%CI: 23.4-1416.6) and nonischemic neurological disorders patients (OR = 26.7; 
95%CI: 5.7-123.7). In 43% of stroke patients aPT were the only antibodies detected 
(Cojocaru et al., 2008). 
The clinical significance of these aPL was also intensively investigated in our studies. Our 
earlier reports demonstrated the usefulness of aPT in diagnosis of APS in SLE patients and 
the highest specificity showed aPT IgG (95.12%). Additionally, aPT IgG were significantly 
associated with selected central nervous system manifestations, and aPT IgM importantly 
influenced risk of development of cardiac complications and mononeuropathy. 
Interestingly, aPT IgA were significantly related to pleurisy and leucopenia, but they did not 
associate with the coexistence of APS (Ostanek et al., 2005). While, our study focused on 
atherosclerotic changes development in SLE patients disclosed a significant influence of aPT 
IgA and AECA on increase of CIMT (Fischer et al., 2007; Fischer et al., 2006). Moreover, this 
finding for aPT IgA was also confirmed by multivariate backward stepwise analysis (Fischer 
et al., 2007).  
The analysis of other aPL in diagnosing APS and their role in main clinical complications 
related to APS showed that anti-phosphatidylserine antibodies (aPS) IgG and IgM are 
valuable diagnostic tool with a high significant predictive value for thrombotic events – 
arterial as well as venous (Lopez et al., 2004; Bertolaccini & Hughes, 2006; Szodoray et al, 
2009). However, the case report of SLE patient with myocardial infarction and without 
associated traditional cardiovascular risk factors and classic aPL disclosed interesting 
relation to aPS IgA suggesting that complete evaluation for aPL should include testing for 
all three isotypes (Jansen et al., 1996). The data on an association between aPS and 
cerebrovascular disorders have been also frequently reported. The study which evaluated 
the relevance of different aPL in patients with cryptogenic stroke and with determined 
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causes of stroke displayed a significant role of aPS IgG and, interestingly, aβ2-GPI IgA in 
stroke etiology (Kahles et al., 2005). Similarly, it was shown in 203 patients suffering from 
ischemic stroke that, in addition to classic aPL, also aPS IgG may be considered risk factors 
for stroke (Saidi et al., 2009). The analysis of 250 persons with cerebral infarction (lacunar, 
atherothrombotic and cardiogenic cerebral embolism) including SLE patients disclosed, 
moreover, that in aPS or anti-phosphatidylinositol (aPI) positive patients an increase of 
CIMT as well as presence of carotid plaques and carotid stenosis ≥ 50% were more frequent. 
Among 250 patients, 13.6% were positive either aPS or aPI and 6.8% were positive for both. 
The majority of patients with aPS and/or aPI were negative for classical aPL (aCL, aβ2-GPI, 
LA). On the other hand, 70.6% of these patients were positive for antinuclear antibodies. The 
authors pointed out that aPL are a risk factor for cerebral infarction especially in SLE 
patients and in younger population (Okuma et al., 2010). Moreover, a significant association 
between CIMT and the risk of ischemic stroke has been well documented (Chambless et al., 
2000; Touboul et al., 2005). 
There is also an increasing evidence of a relationship between the clinical manifestations of 
APS and antibodies directed against phosphatidylethanolamine (aPE) (Mcintyre & 
Wagenknecht, 2000). These antibodies were also often reported as the only aPL particularly 
in patients suffering from thrombotic disease (Bérard et al., 1996; Sanmarco et al., 2001). 
Furthermore, these antibodies, especially IgG isotype, may contribute to detect more 
patients with aPL-related clinical manifestations in SLE patients and their significant 
correlation with valvulopathies and livedo reticularis in patients with SLE was reported 
(Balada et al., 2001). 
The study performed in 185 patients, including SLE patients, suffering from stroke showed 
aPE in 35% of patients. Furthermore, the presence of aPE was the most frequent finding in 
patients who were suspected to have an associated APS (Gonzales-Portillo et al., 2001). The 
next study on young non-SLE patients without obvious causes of arterial thromboembolism 
who underwent ischemic cerebrovascular incidences also demonstrated the presence of 
wide profile of non-cardiolipin aPL, including aPE. However, the frequency of aPE was 
lower – 10.4% (Toschi et al., 1998). In addition, the finding of aPE in the cerebral spinal fluid 
of patient with a documented ischemic stroke may suggest a possibility of an intrathecal 
production of aPL in the course of central nervous system disorders. However, this 
observation needs to be confirmed by further investigations (Sokol et al., 2000). A number of 
reports confirmed also an association between aPE and atherosclerosis. The analysis of the 
clinical features of 20 patients with aPE only, among whom 17 had symptoms potentially 
related to APS, showed significant relationship between aPE and arteriosclerosis with 
peripheral arteriopathy (Desauw et al., 2002).  
Finally, the association between wide profile of aPL including aPS, aPI as well as anti-
phosphatidic acid antibodies and cardiac impairment in lupus patients was reported 
indicating an adjunctive pathogenic role of aPL in these complications (Amoroso et al., 
2006). 
This short description emphasizes that rare non-criteria aPL are associated with selected 
vascular disorders in the course of SLE. The determination of these antibodies may provide 
an additional tool for APS diagnosis and appears to be of interest in patients negative for the 
serologic markers of APS but presenting a clinical picture highly suggestive of this 
syndrome. 
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7. Management and monitoring of atherosclerosis and cardiovascular risk 
factors in systemic lupus erythematosus patients 
European League Against Rheumatism published in 2010 recommendations for monitoring 
SLE patients in clinical practice and in observational studies. It is proposed to assess 
cardiovascular risk factors at baseline and during follow-up at least once a year. Although 
data from the literature have clearly shown that traditional cardiovascular risk factors 
cannot fully explain the increased incidence of atherosclerosis and its complications in this 
patients population, an agreement exists on the need for monitoring conventional risk 
factors and treating modifiable risk factors. The evaluation of cardiovascular risk includes: 
assessment of smoking, vascular events (cerebral/cardiovascular), physical activity, oral 
contraceptive, hormonal therapies and family history of cardiovascular disease, blood 
cholesterol, glucose, blood pressure and body mass index (and/or waist circumference). 
More frequent assessment may be required in certain situations, for instance, in patients on 
glucocorticosteroids therapy (Mosca et al., 2010).  
The guidelines for risk factors management developed to prevent cardiovascular disease in 
SLE patients contain indications regarding ideal targets values for risk factors and 
recommended therapy (Table 1.) (Wajed et al., 2004). 
 
Risk factor Ideal target values
Blood pressure < 130 mmHg systolic and diastolic < 80 mmHg
LDL cholesterol < 2.6 mmol/l
Diabetes mellitus Fasting blood glucose < 7.0 mmol/l
Random blood glucose < 11.0 mmol/l
Smoking Stop smoking
Obesity Body mass index < 25 kg/m2
Table 1. Summary of ideal targets for risk factors in patients with systemic lupus 
erythematosus (Wajed et al., 2004) 
Subjects with SLE tend to develop hypertension more often than general population. The 
drugs indicated as a first line treatment of hypertension in SLE patients are diuretics and 
ACE agents. Treatment with ACE is also recommended  for heart failure, coronary heart 
disease, ventricular hypertrophy or renal failure. These agents are protective of brain stroke 
or microvascular injury in the course of diabetes mellitus (Table 2). Aspirin is an agent of 
proven value in primary and secondary coronary heart disease. It seems to be beneficial in 
terms of survival for SLE patients. However, its universal role for SLE treatment is not 
proven yet, its use is indicated in specific situations like in subjects with previous 
cardiovascular events, smokers, subjects positive for aPL (Table 2) (Wajed et al., 2004). 
Glucocrticosteroids are commonly used in SLE patients and their relation to the risk of 
developing atherosclerotic lesions is now well established (Manzi et al., 1999; McDonald et al., 
1992). On the other hand, antimalarial drugs have been shown to have a beneficial effect in 
SLE (Rahman et al., 1999; Molad et al., 2002). Additionally, in patients with APS 
anticoagulation therapy is used. The long-therm antithrombotic therapy provides protection 
against thrombotic events, but it does not have an antiatherogenic potential (Der et al., 2007).  
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Agent Indication
Aspirin 
Known vascular disease
Systemic lupus erythematosus plus one other risk factor 
Anticardiolipin antibodies/lupus anticoagulant
ACE inhibitors 
Prevalent cardiovascular disease including heart failure 
Left ventricular hypertrophy
Diabetes mellitus
Preferred second drug for hypertension
Table 2. Specific recommendation for aspirin and ACE inhibitors in patients with systemic 
lupus erythematosus (Wajed et al., 2004) 
Moreover, the addition of aspirin also has no significant benefit, so aspirin therapy may not 
be necessary in this group (Wajed et al., 2004).  
Keypoints of APS diagnosis and treatment in patients with acute coronary syndrome are 
summarized in table 3 (Gualtierotti et al., 2011).  
 
Situations when the diagnosis of antiphospholipid syndrome should be taken into account 
in patients with acute coronary syndrome: 
- in young patients (< 55 years in men and < 65 years in women) 
- coronary arteries display normal angiography 
- there are no other traditional cardiovascular risk factors 
- there is no history of drug abuse 
- there are no other causes of heart diseases (congenital abnormalities, etc.) 
Treatment of acute coronary thrombosis is not different in aPL-positive and aPL-negative 
patients 
Anticoagulation with a target INR > 3.0 has been suggested in APS patients with arterial 
thrombosis 
The persistent medium-high aPL is a risk for arterial recurrences and anticoagulation 
should be continued 
The elimination or reduction of other cardiovascular risk is mandatory 
There are no data to recommend additional treatments (aspirin, hydroxychloroquine, or 
statins, etc.) 
Table 3. Antiphospholipid syndrome diagnosis and therapy in patients with acute coronary 
syndrome (Gualtierotti et al., 2011) 
In aPL related atherosclerosis treatment may be directed at managing the effects of aPL or at 
decreasing their titer. In this regard, statins may be potent drugs with positive effect on the 
immune system, vascular endothelium, paraoxonase activity and reduction of inflammation 
(Ames et al., 2009b). Furthermore, biological therapies may be helpful to prevent 
atherothrombotic events in APS/SLE patients (Der et al., 2004). However, anti-CD20 
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accomplished so far lowering of aPL titers in some PAPS patients but not others (Ames et 
al., 2009b). 
8. Conclusions 
Patients with SLE are at risk of accelerated and premature atherosclerosis and cardiac 
complications development. Sensitive noninvasive imaging techniques enable to evaluate 
atherosclerotic changes at every stage of their development and should be commonly used 
for diagnosis and progression monitoring. Traditional risk factors fail to fully account for 
cardiovascular risk in SLE patients. Therefore much attention has been put to investigate the 
role of selected immune mechanisms involved in atherosclerotic lesions pathogenesis. A 
heterogeneous group of antibodies in SLE may accelerate the inflammatory process of 
atherosclerosis. There is a growing body of evidence that aPL may display proatherogenic 
effect in several in vitro and in vivo studies. However, clinical studies provided discrepant 
reports on association between aPL and subclinical atherosclerosis as well as cardiovascular 
manifestations in patients with SLE and large prospective studies are needed to establish the 
role of these autoantibodies in identifying patients at risk. Furthermore, management of 
SLE-related atherosclerosis still remains an unsolved issue. The official recommendations 
and guidelines are focused on traditional modifiable risk factors and conventional 
anticoagulation therapy. The identification of autoantibody biomarkers may provide a 
useful tool to recognize patients with subclinical changes and avoid an irreversible 
cardiovascular damage and, on the other hand, may help to identify new therapeutic goals.  
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